인간 상피 성장 인자 수용체 2 양성 유방암에서 신보조요법 트라스투주맙 엠탄신과 퍼투주맙: 3년 결과, III상 KRISTINE 연구

Hurvitz 등(Mon,)이 이 질문을 연구했습니다.

www.synapsesocial.com/papers/69daaff44a1e15904c835b17 — DOI: https://doi.org/10.1200/jco.19.00882

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. EORTC QLQ-C30 Scoring Manual· 1995 · 2,420 citations
2. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort· 2010 · 1,260 citations
3. Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System· 2007 · 879 citations
4. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update· 2013 · 1,790 citations
5. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update· 2013 · 4,041 citations